Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Theca Steroid-Producing Cell Malignant Tumor Of Ovary, Not Further Specified
Explore 1 assets in Theca Steroid-Producing Cell Malignant Tumor Of Ovary, Not Further Specified →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
University Health Network, Toronto
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06328491CT.gov Erdafitinib in Metastatic Steroid-cell Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Theca Steroid-Producing Cell Malignant Tumor Of Ovary, Not Further Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 (this asset) | University Health Network, Toronto | N/A | D · 30 |
Other indications for Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | B · 60 |
| Bladder Transitional Cell Carcinoma | — | P2 | B · 58 |
| Hepatocellular Carcinoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Theca Steroid-Producing Cell Malignant Tumor Of Ovary, Not Further Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pan-fgfr-tyrosine-kinase-inhibitor-jnj-42756493-theca-steroid-producing-cell-malignant-tumor-of-ovary-not-further-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →